论文部分内容阅读
英明格(Sumatriptan)是一种选择性的类5-HTl_D受体激动剂,临床上用于控制偏头痛发作。其主要机理是选择性收缩已扩张和水肿的颅脑血管,抑制颅内血管无菌性神经源性炎症。本文严格按照国际 Sumatrip-tan 临床试验方法学,观察中国偏头痛患者中服Sumatritan 的疗效。
Sumatriptan is a selective 5-HT1_D-like receptor agonist that is clinically used to control migraine attacks. The main mechanism is the selective contraction of the expansion and edema of the cranial blood vessels, inhibition of aseptic neurogenic inflammation of intracranial blood vessels. This article strictly in accordance with the international Sumatrip-tan clinical trial methodology to observe the efficacy of Sumatritan in migraine sufferers in China.